Lymphoma, Non-HodgkinNCT03117036
Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
An observational study of Lymphoma, Non-Hodgkin and Lymphoma, Hodgkin, run by Samsung Medical Center at 1 site in South Korea.
Trial summary
This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. Read more about this study
- Who is it for?
- Ages 20 to 90 years
- Conditions the study is for
- Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin
- What is being tested?
- Chemotherapy
- How many people
- 600 participants
- Where
- 1 siteSouth Korea
- Study dates
- 1 Mar 2017to 28 Dec 2026
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled
Who may be able to join
- Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
- 20 years
- Patients requiring systemic chemotherapy with curative intent
- Written informed consent
Who cannot join
- Myeloid malignancy
- Multiple myeloma
- Patients do not require systemic chemotherapy with curative intent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea1 site, 1 recruiting
- Recruiting
Samsung Medical Center
Seoul, 135-710
Seok Jin Kim, MD, PhD, 82-2-3410-1766, kstwoh@skku.edu
Seok Jin Kim, MD, PhD
About this study
Official title: A Prospective Study for Patients With Lymphoid Malignancy at the Samsung Medical Center
This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.
Read the detailed description
The study population is aggressive lymphomas requiring systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled into the study. Patients can be treated according to the principle of routine care of our institute. The study process is as follows.
- Registration after informed consent.
- Laboratory and radiological evaluation after registration including collection of serum and cell-free DNA from patients' peripheral blood
- Interim and final response evaluation including collection of serum and cell-free DNA from patients' peripheral blood
- Regular monitoring disease status and update of survival status
- Laboratory and radiological evaluation after relapse or progression including collection of serum and cell-free DNA from patients' peripheral blood
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin
- Being tested
- Chemotherapy
- Keywords
- lymphoma, cohort, serum, cell-free DNA
- Medical subject headings
- Lymphoma, Non-Hodgkin, Hodgkin Disease, Lymphoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ChemotherapyDrug
Also called Treatment
Systemic chemotherapy with curative intent
| Study group | Role | What they receive |
|---|---|---|
| Lymphoma | Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled. Receives: Drug: Chemotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Response rate
response to chemotherapy
Measured: 3 months after chemotherapy
Secondary outcomes (3)
Progression-free survival
Time to relapse/progression or any kinds of death
Measured: 3 year
Overall survival
Time to any kinds of death
Measured: 3 year
Biomarker
Development of biomarker predicting response and survival outcome
Measured: 3 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Apr 2017
- Study start1 Mar 2017
- Primary completion28 Dec 2026 (estimated)
- Study completion28 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lymphoma, Non-HodgkinStudies of the same condition, open and under way.
- More trials run by Samsung Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 600 participants (estimated)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- Samsung Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- Samsung Genomic Institute
- Responsible party
- Sponsor
- Investigators
- Seok Jin Kim, MD, PhD, Principal investigator, Samsung Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03117036
- Sponsor's protocol ID
- 2016-11-040
- Status last verified
- May 2025
- First submitted
- 12 Apr 2017
- Last updated
- 21 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 21 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Study for Patients With Lymphoid Malignancy at the Samsung Medical Center
- ClinicalTrials.gov ID
- NCT03117036
- Acronym / sponsor ID
- 2016-11-040
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin
- Keywords
- lymphoma, cohort, serum, cell-free DNA
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 600 participants (estimated)
- Lead sponsor
- Samsung Medical CenterUniversity, hospital or other
- Collaborators
- Samsung Genomic Institute
- Study start
- 1 Mar 2017 (actual)
- Primary completion
- 28 Dec 2026 (estimated)
- Study completion
- 28 Dec 2026 (estimated)
- First posted
- 17 Apr 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.
Detailed description
The study population is aggressive lymphomas requiring systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled into the study. Patients can be treated according to the principle of routine care of our institute. The study process is as follows.
- Registration after informed consent.
- Laboratory and radiological evaluation after registration including collection of serum and cell-free DNA from patients' peripheral blood
- Interim and final response evaluation including collection of serum and cell-free DNA from patients' peripheral blood
- Regular monitoring disease status and update of survival status
- Laboratory and radiological evaluation after relapse or progression including collection of serum and cell-free DNA from patients' peripheral blood
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Lymphoma | – | Drug: ChemotherapyPatients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled. |
Who may qualify
- Ages
- 20 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled
Key inclusion criteria (4 listed)
- Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
- 20 years
- Patients requiring systemic chemotherapy with curative intent
- Written informed consent
Key exclusion criteria (3 listed)
- Myeloid malignancy
- Multiple myeloma
- Patients do not require systemic chemotherapy with curative intent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ChemotherapyAlso: TreatmentSystemic chemotherapy with curative intent | Drug | Lymphoma |
Primary outcome
Response rate
Time frame: 3 months after chemotherapy
response to chemotherapy
3 secondary outcomes
Progression-free survival
Time frame: 3 year
Overall survival
Time frame: 3 year
Biomarker
Time frame: 3 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 May 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Lymphoma, Non-Hodgkin
RecruitingPhase 2
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Non-hodgkin Lymphoma
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
Active, not recruitingPhase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative
Active, not recruitingPhase 1/2
Study of Oral MRT-2359 in Selected Cancer Patients
NSCLC, SCLC
Active, not recruitingObservational study
Multi-omics Profiling of Relapsed Extranodal Natural Killer (NK)/T-cell Lymphoma
Extranodal NK/T-cell Lymphoma, Nasal Type
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Seok Jin Kim, MD, PhD principal investigator
Samsung Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lymphoma, Non-Hodgkin and Lymphoma, Hodgkin, run by Samsung Medical Center at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Seok Jin Kim, MD, PhD (+82234101766, kstwoh@skku.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Response rate (time frame: 3 months after chemotherapy). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 May 2025.